Skip to main content
SpringerLink
Log in

Role of GnRH Agonists for Fertility Preservation in Breast Cancer

  • Chapter
  • First Online:
Fertility Challenges and Solutions in Women with Cancer

  • 387 Accesses

Abstract

A large fraction of young breast cancer patients are concerned about their chances of future fertility. Chemotherapy often results in premature ovarian failure, particularly in women over the age of 35. Recent trials have suggested that concomitant administration of gonadotropin-releasing hormone agonists (GnRHa) with chemotherapy reduces the risk of premature ovarian failure. This option is currently endorsed by several international and local guidelines, and in some countries it is being covered by healthcare insurance as well. In this chapter, we discuss the clinical data supporting the use of GnRHa in early breast cancer for ovarian protection and fertility preservation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013.. http://globocan.iarc.fr/

    Google Scholar 

  2. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131(3):1061–6.

    Article  CAS  PubMed  Google Scholar 

  3. Partridge AH, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, et al. The effect of age on delay in diagnosis and stage of breast cancer. Oncologist. 2012;17(6):775–82.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Poggio F, Levaggi A, Lambertini M. Chemotherapy-induced premature ovarian failure and its prevention in premenopausal breast cancer patients. Expert Rev Quality Life Cancer Care. 2016;1(1):5e7.

    Article  Google Scholar 

  5. ESHRE Guideline Group on POI, Webber L, Davies M, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–37.

    Article  Google Scholar 

  6. Sawe BE. Countries with the oldest average mother’s age at first birth. 15 Aug. 2016. www.worldatlas.com/articles/countries-with-the-highest-mother-s-mean-age-at-first-birth.html.

  7. Mathews TJ, Hamilton BE. Mean age of mothers is on the rise: United States, 2000–2014. NCHS Data Brief. 2016;232:1e8.. http://www.ncbi.nlm.nih.gov/pubmed/26828319.

    Google Scholar 

  8. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–83.

    Article  PubMed  Google Scholar 

  9. Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist. 2013;18(12):1298–306.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Villarreal-Garza C, Platas A, Bargalló-Rocha JE, et al. Cáncer de mama en mujeres jóvenes: Experiencia en el Instituto Nacional de Cancerología. Rev Mex Mastol. 2015;5(1):12–7.

    Google Scholar 

  11. Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151e6.

    Article  Google Scholar 

  12. Letourneau JM, Ebbel EE, Katz PP, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118:17 10–7.

    Article  Google Scholar 

  13. Villarreal-Garza C, Martinez-Cannon BA, Platas A, et al. Fertility concerns among breast cancer patients in Mexico. Breast. 2017;33:71–5.

    Article  PubMed  Google Scholar 

  14. Litton JK. Breast cancer and fertility. Curr Treat Options Oncol. 2012;13:137–45.

    Article  PubMed  Google Scholar 

  15. Paluch-Shimon S, Pagani O, Partridge AH, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203–17.

    Article  PubMed  Google Scholar 

  16. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001.

    Article  PubMed  Google Scholar 

  17. Lambertini M, Goldrat O, Barragan-Carrillo R, et al. Viable options for fertility preservation in breast cancer patients: a focus in Latin America. Rev Invest Clin. 2017;69:103–13.

    CAS  PubMed  Google Scholar 

  18. Lambertini M, Goldrat O, Clatot F, et al. Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. Curr Opin Oncol. 2017;29:243–52.

    Article  PubMed  Google Scholar 

  19. Gründker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003;1:65.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin’s disease. Blood. 1981;58:849–51.

    Article  CAS  PubMed  Google Scholar 

  21. Li M, Huang H, Liang Y, Tan J, Lin D. Effect of Zoladex administered before chemotherapy on menstruation of patients with breast cancer. Chin J Clin Oncol. 2008;35:905–7.

    Google Scholar 

  22. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117:561–7.

    Article  CAS  PubMed  Google Scholar 

  23. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29:2334–41.

    Article  CAS  PubMed  Google Scholar 

  24. Sun J, Ren Y, Li W. Effect of Zoladex administered before chemotherapy on menstruation of patients with breast cancer. China Disabil Med. 2011;19:15–6.. n.d

    Google Scholar 

  25. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30:533–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013;121:78–86.

    Article  CAS  PubMed  Google Scholar 

  27. Jiang FY, Zhang QQ, Zeng J. Protective effect of GnRHa on chemotherapy Induced ovarian damage in breast cancer patients. Shandong Med J. 2013;53(8):16–8.

    Google Scholar 

  28. Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR, Nakhaie-Moghadam M, Miratashi-Yazdi A, Teimoori S, et al. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol. 2014;35:59–61.

    CAS  PubMed  Google Scholar 

  29. Song G, Gao H, Yuan Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol. 2013;30:667.

    Article  PubMed  CAS  Google Scholar 

  30. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306:269–76.

    PubMed  Google Scholar 

  31. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314:2632–40.

    Article  CAS  PubMed  Google Scholar 

  32. Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230. JNCI J Natl Cancer Inst. 2019;111(2):djy185.

    Article  Google Scholar 

  33. Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28:1811–6.

    Article  CAS  PubMed  Google Scholar 

  34. Zhang Y, Ji Y, Li J, Lei L, Wu S, Zuo W, et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Res Treat. 2018;168:679–86.

    Article  CAS  PubMed  Google Scholar 

  35. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91:694–7.

    Article  CAS  PubMed  Google Scholar 

  36. Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA, Ugolini D, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26:2408–19.

    Article  CAS  PubMed  Google Scholar 

  37. Bai F, Lu Y, Wu K, Chen Q, Ding L, Ge M, et al. Protecting effects of gonadotropin releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients: a systematic review and meta-analysis. Breast Care. 2017;12:48–52.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Munhoz RR, Pereira AAL, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and metaanalysis. JAMA Oncol. 2016;2:65–73.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018;36:1981–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Shen Y-W, Zhang X-M, Lv M, Chen L, Qin T-J, Wang F, et al. Utility of gonadotropinreleasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. OncoTargets Ther. 2015;8:3349–59.

    Article  Google Scholar 

  41. Yang B, Shi W, Yang J, Liu H, Zhao H, Li X, et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast. 2013;22:150–7.

    Article  PubMed  Google Scholar 

  42. Wang C, Chen M, Fu F, Huang M. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PLoS One. 2013;8:e66360.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Silva C, Caramelo O, Almeida-Santos T, Ribeiro Rama AC. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod. 2016;31:2737–49.

    Article  PubMed  Google Scholar 

  44. Azim HA Jr, Davidson NE, Ruddy KJ. Challenges in treating premenopausal women with endocrine-sensitive breast cancer. Am Soc Clin Oncol Educ Book. 2016;35:23–32.

    Article  PubMed  Google Scholar 

  45. Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2017;71:25e33.

    Google Scholar 

  46. Lambertini M, Di Maio M, Pagani O, et al. The BCY3/BCC 2017 survey on physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. The Breast. 2018;42:41–9.

    Article  PubMed  Google Scholar 

  47. Villarreal-Garza CM, Barragan-Carillo R, Bargallo-Rocha JE, et al. Physicians’ knowledge and attitudes towards fertility preservation in Mexican young breast cancer patients. Cancer Res. 2018;78(4 Suppl). P6-11-09.

    Google Scholar 

  48. Biglia N, Torrisi R, D’Alonzo M, Codacci Pisanelli G, Rota S, Peccatori FA. Attitudes on fertility issues in breast cancer patients: an Italian survey. Gynecol Endocrinol. 2015;31(6):458e64.

    Article  Google Scholar 

  49. Lambertini M, Fontana V, Massarotti C, et al. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. The Breast. 2018;41:51–6.

    Article  PubMed  Google Scholar 

  50. Snyder KA, Pearse W. Discussing fertility preservation options with patients with cancer. JAMA. 2011;306:202–3.

    Article  CAS  PubMed  Google Scholar 

  51. Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol. 2005;23:766–73.

    Article  PubMed  Google Scholar 

  52. Rashedi AS, De Roo SF, Ataman LM, et al. Survey of fertility preservation options available to patients with cancer around the globe. J Glob Oncol. 2018;4:1–16.

    Article  Google Scholar 

  53. Cohen L, Hamer J, Helwig C, et al. Formal evaluation of PYNK: breast cancer program for young women-the patient perspective. Curr Oncol Tor Ont. 2016;23:e102–8.

    Article  CAS  Google Scholar 

  54. Villarreal-Garza C, Castro-Sanchez A, Platas A, et al. “Joven & Fuerte”: program for young women with breast cancer in Mexico—initial results. Rev Invest Clin. 2017;69:223–8.

    PubMed  Google Scholar 

  55. Villarreal-Garza C, Platas A, Bargallo-Rocha JE, et al. Characterization of young Mexican patients with breast cancer who underwent oocyte/embryo preservation. The Breast. 2018;41:S9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Zambrano Hellion—Breast Cancer Center, Tecnologico de Monterrey, School of Medicine, Monterrey, NL, Mexico

    Cynthia Villarreal-Garza, Edna A. Lopez-Martinez & Hatem A. Azim Jr

  2. Research and Breast Cancer Department, Instituto Nacional de Cancerologia, Mexico City, Mexico

    Cynthia Villarreal-Garza

  3. Joven & Fuerte, Program for Young Women with Breast Cancer in Mexico, Mexico City, Mexico

    Cynthia Villarreal-Garza & Edna A. Lopez-Martinez

Authors
  1. Cynthia Villarreal-Garza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edna A. Lopez-Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hatem A. Azim Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, Tecnologico de Monterrey, Monterrey, Mexico

    Hatem A. Azim Jr

  2. CUB-Erasme, Fertility Clinic, Université Libre de Bruxelles, Brussels, Belgium

    Isabelle Demeestere

  3. Division of Gynecologic Oncology, European Institute of Oncology, Milan, Italy

    Fedro A. Peccatori

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Villarreal-Garza, C., Lopez-Martinez, E.A., Azim, H.A. (2020). Role of GnRH Agonists for Fertility Preservation in Breast Cancer. In: Azim Jr, H., Demeestere, I., Peccatori, F. (eds) Fertility Challenges and Solutions in Women with Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-24086-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24086-8_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-24085-1

  • Online ISBN: 978-3-030-24086-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation